Rapid Micro Biosystems (RPID) Q2 FY26 earnings call

Rapid Micro Biosystems delivered a strong Q2 FY26, surpassing revenue guidance with record consumable sales and significant gross margin expansion driven by operational efficiencies. The company is seeing increasing adoption of its GrowthDirect platform, expanding its installed base and recurring revenue, and is confident in its path to positive cash flow by the end of 2028, supported by strategic partnerships and industry tailwinds. Management reaffirmed full-year revenue and placement guidance while raising validation targets.